Editas Medicine, Inc.

NASDAQ:EDIT

Biotechnology

Healthcare
$1.77 +2.65%

+$0.07 today

Market cap
$273.18M
Beta
2.10
P/E (TTM)
-2.4
EPS (TTM)
-$1.11
52W Low $1.66High $4.54

Volume 1.99M

Average 2.06M

EDIT Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Editas Medicine, Inc.NASDAQ: EDIT

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development declines year over year

Q1 FY2026 research & development of $2.83M fell 89.4% year over year, behind the -62.3% change in trailing-twelve-month research & development. Sequentially, it fell 89.7% from the prior quarter. Over 3 fiscal years it compounded at -19.9% a year.

Context

  • Research & development amounted to 222.0% of revenue in FY2025, down 394.6 pp from a year earlier.
  • Research & development increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -89.4% toward the trailing-twelve-month pace of -62.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.83M-89.7% QoQ
Last fiscal yearDec 2025
$89.95M-54.9% YoY
LTMMar 2026
$66.19M-62.3% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-89.4%——
1 year-54.9%——
3-year CAGR-19.9%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
89.95M USD
Year-over-year change
-54.9%
4-year CAGR
-10.9%

Research & Development vs competitors

How EDIT compares with its peers on the latest reported figures

  • EDIT's LTM Mar 2026 research & development of $66.19M is the 7th highest of the 9 companies compared; the peer median is $145.85M.
  • Its year-over-year change of -62.3% is the lowest of 9, against a peer median of -6.6%.
  • Research & development amounts to 171.1% of revenue for EDIT, versus a peer median of 695.1%.
EDIT Competitors Peer median
Research & Development for EDIT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BEAMBeam Therapeutics Inc.LTM Jun 2026$408.66M +3.1%+9.5%261.9%
NTLAIntellia Therapeutics, Inc.LTM Mar 2026$361.17M -21.5%-2.5%546.5%
CRSPCRISPR Therapeutics AGLTM Sep 2026$283.28M +1.6%-16.9%1125.4%
PRMEPrime Medicine, Inc.LTM Mar 2026$154.18M -2.5%+22.8%3822.0%
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026$137.53M -14.3%-5.0%—
CRBUCaribou Biosciences, Inc.LTM Mar 2026$94.52M -28.3%+10.0%843.7%
EDITEditas Medicine, Inc.LTM Mar 2026$66.19M -62.3%-19.9%171.1%
DTILPrecision BioSciences, Inc.LTM Mar 2026$53.36M -10.8%+5.5%118.4%
BNTCBenitec Biopharma Inc.LTM Mar 2026$19.2M +1.2%+17.6%—
SCTXScribe Therapeutics Inc.—— ———
Peer median (excluding EDIT) $145.85M-6.6%+7.5%695.1%

Competitors are the stored peer set for EDIT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue25.54M19.71M78.12M32.31M40.52M
Cost of Revenue5.05M6.34M6.06M199.25M0
Gross Profit20.49M13.38M72.06M(166.93M)40.52M
Gross Margin80.2%67.9%92.2%-516.6%100.0%
Research & Development142.51M174.96M177.65M199.25M89.95M
Selling, General & Admin76.18M70.7M69.65M71.99M49.9M
Operating Expenses213.64M239.33M241.24M84.22M139.86M
Depreciation & Amortization5.05M6.34M6.06M5.81M5.28M
EBITDA(187.45M)(214.1M)(147.16M)(233.11M)(148.61M)
EBITDA Margin-733.8%-1086.1%-188.4%-721.4%-366.8%
Operating Income(193.15M)(225.95M)(169.18M)(251.15M)(99.34M)
Operating Margin-756.1%-1146.3%-216.6%-777.2%-245.2%
Interest Income607K5.52M17.57M14.06M8.31M
Interest Expense00006.17M
Other Income / Expenses644K5.52M15.96M14.06M(60.72M)
Income Before Tax(192.5M)(220.43M)(153.22M)(237.09M)(160.06M)
Pre-Tax Margin-753.6%-1118.3%-196.1%-733.7%-395.0%
Income Tax Expense00000
Net Income(192.5M)(220.43M)(153.22M)(237.09M)(160.06M)
Net Margin-753.6%-1118.3%-196.1%-733.7%-395.0%
EPS (Basic)(2.85)(3.21)(2.02)(2.88)(1.80)
EPS (Diluted)(2.85)(3.21)(2.02)(2.88)(1.80)
Weighted Avg Shares67.62M68.66M75.97M82.34M88.75M
Weighted Avg Shares (Diluted)67.62M68.66M75.97M82.34M88.75M

Editas Medicine, Inc.

NASDAQ:EDIT

Intrinsic Alpha fair value

Locked

Current Price

$1.77

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.